It's a one-dose vaccine that can be kept stable at typical refrigerator temperatures for several months.
The company's Covid-19 vaccine, if approved, would be especially helpful to the nation's supply because it is created to work with just one dose. News of supply disruptions for the AstraZeneca and Pfizer vaccines has been surfacing in Europe, and USA rollouts for the mRNA vaccines have gotten off to a slower-than-expected start. If the data are positive, that could "could meaningfully accelerate the rollout of vaccinations across the U.S." and "potentially disrupt other vaccine manufacturers' demand expectations", Barclays analyst Carter Gould wrote in a note to clients Tuesday. The mRNA shots from Pfizer and Moderna require deep-freeze temps as low as 94 degrees below zero Fahrenheit.
"In terms of supply we're very confident", chief financial officer said.
The vaccine could become the third to receive emergency use authorization in the US, likely in February, following Pfizer and BioNTech, who won the first Food and Drug Administration emergency clearance, and Moderna.
The drugmaker has agreed to supply 100 million doses to the USA, plus 200 million to Europe and 100 million to developing countries through Gavi, the Vaccine Alliance.
Governors are pushing the federal government to ship more doses to their states so they can vaccinate a broader range of residents and bring the pandemic to manageable levels.
USA officials are desperate to gain approval of J&J's one-dose vaccine as the pandemic claims thousands of lives per day and governors clamor for more supply. The shipments to developing countries will begin in the second half of the year, he said.
Johnson & Johnson said on Tuesday it planned to release much-awaited data on its COVID-19 vaccine early next week and that it would be able to meet the target of delivering doses to countries with whom he had signed supply agreements.
"2020 was obviously a bumpy year, but we never took our focus off the long-term", Wolk said.
Merck & Co.is discontinuing development of its Covid-19 vaccine after results from a clinical trial showed disappointing results, the company said Monday. The company told Bloomberg earlier this month that it remains on track to hit the goal of producing 1 billion doses before year-end. But because there are still many moving parts, the company didn't provide financial guidance for the shot, which could deliver a sizable revenue boost this year.
J&J forecasts adjusted earnings for 2021 of between $ 9.40 and $ 9.60 per share, compared to analysts' estimates of $ 8.99 per share, according to IBES data from Refinitiv. The company's pharma business stood out among its counterparts, generating $45.6 billion in revenues and posting 8% reported growth.
A big jump in prescription drug sales boosted fourth-quarter sales at Johnson & Johnson, but profits dove 57% due to higher research spending and one-time charges totaling $2.4 billion. Eastern. Questions about the vaccine program are likely.